Core Viewpoint - The stock of Giant Bio (02367) has dropped over 4%, halving from its year-to-date high of 85.79 HKD, currently trading at 39.22 HKD with a transaction volume of 745 million HKD [1] Group 1: Company Performance - Giant Bio's subsidiary, Kefu Mei, has shown lackluster performance in pre-sales during this year's "Double Eleven" event [1] - According to Citigroup's report, the main products of Giant Bio experienced a decline in performance during the pre-sale on October 15 in Li Jiaqi's live streaming session [1] - Citigroup noted that the company's promotional strategy has become more stringent, making its pricing less attractive compared to other brands [1] Group 2: Market Reaction and Future Outlook - Citigroup believes that the market's reaction to the decline in pre-sale performance during the Double Eleven event is overly pessimistic [1] - Although Li Jiaqi's live streaming sales trend is an important indicator for Double Eleven performance, the contribution from this channel has significantly decreased due to the growth of other KOLs and the company's own live streaming efforts [1] - Despite the intense competition, there has been no negative feedback from customers regarding the company's products or brand [1] - Given the low base this year, Citigroup expects Giant Bio's sales to recover in the fiscal year 2026, and the company's valuation remains attractive [1]

Core Viewpoint - The stock of Giant Bio (02367) has been transferred from the Shenzhen-Hong Kong Stock Connect to the Shanghai-Hong Kong Stock Connect, with a market value of HKD 887 million, accounting for 2.05% of the total [1] Group 1: Company Performance - Citigroup predicts that Giant Bio's performance in Q3 and the first two weeks of October is relatively weak due to fewer KOL live streams [1] - The expected revenue growth for Giant Bio in the second half of the year is 16% year-on-year, with Tmall projected to decline by 10%, Douyin to increase by 25%, JD.com to grow by 100%, and offline sales to rise by 10% [1] - Citigroup also anticipates that Giant Bio's revenue for the fiscal year 2026 will continue to grow at a high rate of 19% from a low base, as there are no negative feedbacks from customers [1]

Core Viewpoint - The recent stock transfer of Giant Bio (02367) from Hong Kong Stock Connect (Shenzhen) to Hong Kong Stock Connect (Shanghai) indicates a strategic shift, with a market capitalization of HKD 887 million, representing 2.05% of the total [1] Group 1: Company Performance - Citigroup predicts that Giant Bio's performance in Q3 and the first two weeks of October is relatively weak due to fewer KOL live streams [1] - The revenue growth forecast for the second half of the year is 16% year-on-year, with specific expectations of a 10% decline on Tmall, a 25% increase on Douyin, a 100% increase on JD.com, and a 10% growth offline [1] - Citigroup anticipates that Giant Bio's revenue will continue to grow at a high rate of 19% in the fiscal year 2026, supported by a low base and no negative feedback from customers [1]

Summary of the Conference Call for 巨子生物 Company Overview - The conference call pertains to 巨子生物, a company involved in the beauty and skincare industry, specifically focusing on collagen products. Key Points and Arguments - **Crisis During 618 Sales Event**: 巨子生物 faced a public relations crisis during the 618 sales period due to criticism from influencer "大嘴博士" regarding their flagship product, 可复美胶原棒. The influencer claimed that the product contained insufficient levels of recombinant collagen protein, leading to significant returns and negative reviews, which adversely affected sales [3][4]. - **Impact of Influencer Marketing**: Despite the initial backlash, signs indicate that the negative impact is diminishing. Prominent influencers such as 李佳琦 and 贾乃亮 have resumed promoting 可复美胶原棒, suggesting a recovery in public sentiment towards the product [3][5]. - **Sales Performance**: From the 618 period through Q2 and Q3, 巨子生物's sales were consistently affected by the aforementioned public relations issue. However, recent developments indicate that the influence of the crisis is waning, as major platforms like 天猫 and 抖音 see a return of influencer promotions for the product [5]. Additional Important Information - **Product Composition Controversy**: The controversy centered around the product's composition, where it was noted that the recombinant collagen protein was present at only 0.01%, below the 0.1% threshold required for labeling in cosmetics. Additionally, the form of collagen in the product was identified as peptides, lacking the triple helix structure typically associated with collagen [4]. - **Market Sensitivity**: The behavior of top and mid-tier influencers is highly sensitive to market sentiment. Their decision to resume promotions indicates a belief that the product is no longer under severe negative scrutiny, which is a positive sign for 巨子生物's recovery [3][5].

Core Viewpoint - The competition in the collagen industry is intensifying, with two regional female tycoons leading their respective companies into the spotlight, highlighting a shift from B2B to B2C markets in the beauty sector [2] Group 1: Company Strategies - Juzhi Biotechnology, led by Fan Daidi, was once a benchmark in the industry but is now facing competition from Jinbo Biotechnology, which is entering the consumer skincare market with its new brand "Tongping" [2] - Jinbo's founder, Yang Xia, has made a rare public appearance to support the "Tongping" brand, signaling a strategic shift from medical devices to beauty products [2] Group 2: Market Dynamics - The competition began in e-commerce live streaming, where "Tongping" quickly gained traction, ranking second in GMV growth during Li Jiaqi's first live stream of this year's Double Eleven shopping festival [2] - The entry of Jinbo into the collagen market poses a direct challenge to Juzhi, as both companies utilize similar traffic-driven sales strategies and product types [2] - The ability of Jinbo to leverage its pharmaceutical background to outperform Juzhi will significantly influence the future landscape of the collagen market [2]

Core Viewpoint - The article highlights the declining performance of Juzhibio (巨子生物) and its main brand, Kefu Mei (可复美), during the "Double Eleven" pre-sale period, leading to a significant drop in stock price and market value [3][5]. Company Performance - Juzhibio's stock price fell to a new low of HKD 40.40 per share, with a total market value of HKD 43.3 billion, marking a 53.46% decline from its peak of HKD 86.8 per share in May [3][5]. - Kefu Mei's sales during the "Double Eleven" pre-sale were underwhelming, with a reported GMV of HKD 0.5-0.75 billion on Douyin, down from over HKD 1 billion in the same period last year [3][4]. Market Competition - The market for recombinant collagen products is growing rapidly, with a projected CAGR of 44.93%, expected to reach RMB 2,193.8 billion by 2030 [6]. - Juzhibio's revenue is forecasted to increase from RMB 2.364 billion in 2022 to RMB 5.539 billion in 2024, while its net profit is expected to rise from RMB 696 million to RMB 2.062 billion in the same period [6]. Brand Strategy and Challenges - Kefu Mei has faced challenges due to a previous controversy regarding its collagen stick product, which has negatively impacted its sales performance [3][4]. - Juzhibio's marketing expenses reached HKD 10.58 billion in the first half of the year, accounting for 34.01% of total revenue, as the company seeks to maintain growth amid increasing competition [7].

Group 1 - The stock of Hong Kong-listed company Giant Bio (02367.HK) opened high but experienced a decline, with a drop of nearly 3% in the afternoon session [2] - As of the report, the stock price decreased by 2.92%, trading at 40.6 HKD, with a transaction volume of 678 million HKD [2]

Group 1 - The core viewpoint of the news is that the market's reaction to the pre-sale performance of Giant Bio during the live broadcast by influencer Li Jiaqi is considered excessive, as the company's promotional strategy has made its products less price-attractive compared to competitors [1][2] - Giant Bio's stock price has seen significant volatility, with a drop of over 15% recently and reaching a new low of 40.6 HKD, reflecting investor concerns about its sales performance [1] - Citigroup's report indicates that the company's revenue growth is expected to be 16% year-on-year in the second half of the year, despite a projected decline of 10% on Tmall [2] Group 2 - Citigroup predicts that Giant Bio's sales will recover in the fiscal year 2026, with a high growth rate of 19% due to a low base and no negative customer feedback [2] - The target price for Giant Bio's stock has been adjusted from 69.4 HKD to 55.4 HKD based on a 20 times price-to-earnings ratio for the fiscal year 2026, while maintaining a "buy" rating [2] - The performance of KOL live broadcasts is noted to be declining, impacting the company's sales, with expectations of a 25% increase on Douyin and a 100% increase on JD, while offline sales are expected to grow by 10% [2]

Core Viewpoint - The stock of Giant Bio (02367) has experienced significant volatility, with a recent drop of nearly 3% after a previous decline of over 15%, reaching a new low of 40.6 HKD, attributed to market reactions to its pre-sale performance during a major live-streaming event [1] Group 1: Stock Performance - Giant Bio's stock opened high but fell sharply, with a midday drop of nearly 3%, and a previous day decline exceeding 15% [1] - The stock price hit a new low of 40.6 HKD, marking the lowest point in over a year [1] - As of the latest update, the stock was down 2.92%, with a trading volume of 678 million HKD [1] Group 2: Market Analysis - Citigroup's report indicates that the market's reaction to Giant Bio's pre-sale performance during the live-streaming event with influencer Li Jiaqi was excessive [1] - The report highlights that Giant Bio's main products were less price-competitive due to stricter promotional strategies compared to other brands [1] - Citigroup predicts a relatively weak performance for Giant Bio in Q3 and the first two weeks of October, primarily due to fewer KOL live-streaming events [1] Group 3: Revenue Forecast - Citigroup forecasts a 16% year-on-year revenue growth for Giant Bio in the second half of the year, with specific expectations of a 10% decline on Tmall, a 25% increase on Douyin, a 100% growth on JD, and a 10% increase in offline sales [1] - For the fiscal year 2026, Citigroup anticipates a continuation of high growth at 19% due to a low base and no negative customer feedback [1] - The target price for Giant Bio has been adjusted from 69.4 HKD to 55.4 HKD based on a 20x price-to-earnings ratio for the fiscal year 2026, while maintaining a "buy" rating despite lowering profit forecasts [1]

Group 1 - The "Double Eleven" shopping festival for 2025 has quietly begun, with a focus on the cosmetics sector experiencing a weaker Q3 due to seasonal trends [1] - According to data from Chian Mama, some key brands have shown a decline in growth rates on Douyin in Q3, with Juzhi Biological's GMV increasing by 15% year-on-year, while Kefu Mei and Keli Jin saw increases of 5% and 78% respectively [1] - Juzhi Biological is expected to focus on boosting sales during the upcoming Double Eleven event in the second half of the year [1] Group 2 - Huaxi Biological has reported issues regarding the collagen products, stating that multiple third-party testing results indicated that the added amount of recombinant collagen in related products did not meet standards [2] - Huaxi Biological has submitted dozens of test reports to the National Medical Products Administration [2]